Physician profile
Harris Waheed
NPI 1164511580
$13,536.83
in general payments reported to CMS, 2019-2025
43 companies · $1,980 in 2025
The $1,980 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $908 · 2020: $1,220 · 2021: $2,476 · 2022: $2,431 · 2023: $1,993 · 2024: $2,530 · 2025: $1,980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,458 · Education: $43.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,458.47 |
| Education | $43.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,709.28 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,530.01 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Nestle Healthcare Nutrition INC. | $1,484.43 | 2020-2023 | |
| Lilly USA, LLC | $1,101.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,056.99 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $939.22 | 2019-2025 | Jardiance |
| Aimmune Therapeutics, INC. | $835.24 | 2024-2025 | Zenpep |
| Glaxosmithkline, LLC. | $766.56 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $503.03 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $340.41 | 2019-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $332.91 | 2023-2025 | Voquezna |
| Amgen INC. | $295.45 | 2019-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $274.78 | 2019-2023 | Belsomra, Steglatro |
| Almatica Pharma LLC | $222.04 | 2021-2024 | Loreev Xr, Sertraline Hcl, Gralise |
| Takeda Pharmaceuticals U.S.A., INC. | $190.67 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harris Waheed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.